The Bull Rankings scorecard — our quality-growth score is 81.3 / 100, built from three pillars each graded 0–100 against sector peers: Quality 84, Growth 77, Value 83. At today's price, our reverse-DCF read says the market is implicitly betting on about 4% a year in free-cash-flow growth sustained for a decade — a gauge of how much optimism is already in the stock.
The thesis
ADMA Biologics is a value‑oriented compounder that the market is punishing far beyond its fundamentals. At $9.76 a share the stock trades at a P/E of 13.9 and a PEG of 0.6, implying cheap earnings relative to growth. Coupled with a 33% profit margin and ROE of 41.4%, the numbers scream a high‑return business that the market has undervalued—evidenced by the 52‑week low of $7.21 versus a current price barely half its 52‑week high of $20.46. Our model’s Quality‑growth score of 81.3 reflects this, with Quality (84) as the strongest pillar, underscoring the durability of those returns, while Growth (77) is the weakest, flagging modest top‑line expansion. The thesis is that the market’s pessimism over growth is overstated, leaving a sizable upside.
What the business actually is
ADMA manufactures specialty plasma‑derived biologics for immune deficiencies and infectious disease. Its flagship products are BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) therapies for primary humoral immunodeficiency, and Nabi‑HB, a polyclonal antibody for acute Hepatitis B exposure. Revenue streams flow from the ADMA BioManufacturing segment, which produces and markets these biologics, and the Plasma Collection Centers segment that secures the raw plasma. The IVIG line, especially ASCENIV, drives the growth narrative, while Nabi‑HB adds a niche defensive layer in the infectious‑disease space.
Why it can (or can't) keep compounding
The strongest signal from our model is Durable high returns. A ROE of 41.4% and profit margin of 33% place ADMA in the upper‑quartile of biotech peers, indicating that each dollar of equity is turned into a hefty profit. This profitability stems from a high‑barrier plasma collection network and a proprietary purification process that few competitors can replicate quickly. The IVIG market is fragmented, but ADMA’s dual‑product strategy (BIVIGAM and ASCENIV) gives it pricing power and a diversified customer base across hospitals and specialty clinics. Moreover, the beta of 0.77 suggests lower volatility than the sector, reinforcing the defensive nature of its cash flows. The debt‑to‑equity of 1.11 is modest for a capital‑intensive biotech, leaving room for the Buying back stock signal to further boost per‑share metrics without jeopardizing balance‑sheet health.
The valuation question
The market is pricing in roughly 4% annual free‑cash‑flow growth for the next decade, per our reverse‑DCF. That is starkly lower than the 8% FY YoY revenue growth reported, and far beneath the 41.4% ROE that suggests the business can reinvest earnings at a much higher clip. The PEG of 0.6 already flags that earnings are expected to outpace growth, yet the implied FCF trajectory is conservative. In other words, the current price embeds a pessimistic view of top‑line expansion while ignoring the high return on capital. The analyst consensus 1‑yr target of $17 and a range of $12–$21 indicate that some sell‑side participants see upside, but the market’s 52‑week low suggests a discount that exceeds the downside risk implied by the PE of 13.9. If ADMA can sustain its margin and reinvest at its current ROE, the fair‑value should be materially higher than the $9.76 price.
The bear case
Skeptics point to the Growth pillar (77) as the weakest link, arguing that an 8% revenue growth rate is modest for a biotech still expanding its product footprint. The recent slashed outlook reported on August 18, which triggered a share tumble, underscores management’s caution amid competitive headwinds (Stocktwits). If the ASCENIV pipeline stalls or reimbursement pressures bite, growth could flatten, making the 4% implied FCF growth realistic rather than optimistic. The Bernstein Liebhard investigation into potential fiduciary breaches adds governance risk; a material finding could force capital allocation away from buybacks and toward remediation, eroding the Durable high returns signal.
What would change our mind
- Revenue growth accelerates: If ADMA reports FY YoY growth above 12% in the next quarter, the gap between actual growth and the 4% reverse‑DCF assumption would widen, confirming that the market is undervaluing the upside.
- Buyback execution: A disclosed repurchase program exceeding $200 million within the next 12 months would validate the Buying back stock signal and lift EPS, tightening the valuation multiple.
- Growth pillar erosion: Should ROE dip below 35% or profit margin fall under 30% for two consecutive quarters, the Quality advantage would weaken, justifying the current discount and prompting a reassessment of the thesis.